What a brutal six months it’s been for DexCom. The stock has dropped 32.6% and now trades at $58.63, rattling many ...

Ever wondered if DexCom is now a bargain or still priced for perfection? Let's get under the hood to see if the recent headlines match up with what the numbers are really saying. The stock has seen ...

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an ...

Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

Now, it’s worth noting Stock Advisor’s total average return is 1,064% — a market-crushing outperformance compared to 194 % ...

Investors considering a purchase of DexCom Inc (Symbol: DXCM) shares, but cautious about paying the going market price of $80.15/share, might benefit from considering selling puts among the ...

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...

Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...

DexCom, Inc. DXCM reported second-quarter 2025 results that highlighted robust top-line growth, continued progress in expanding access and meaningful product innovation. Revenues grew 15% year over ...